What's Happening?
The Critical Path Institute (C-Path) is set to host its 2026 Global Impact Conference (CGIC) in Washington, D.C., from September 15-16, with a special session on September 17. The conference will focus on establishing a new paradigm for generating evidence
of drug efficacy and safety. Keynote speakers include Michael Davis, M.D., Ph.D., acting director of the FDA's Center for Drug Evaluation and Research, and Janet Woodcock, M.D., former principal deputy commissioner of the FDA. The event will bring together leaders from regulatory agencies, the pharmaceutical industry, academia, and advocacy groups to address challenges in drug development. The agenda includes discussions on artificial intelligence, real-world data, digital health technologies, and biomarker development.
Why It's Important?
This conference is significant as it addresses critical challenges in drug development, particularly the need for a new paradigm in evidence generation. By bringing together diverse stakeholders, the event aims to foster collaboration and innovation in the pharmaceutical industry. The focus on modernizing evidence generation could lead to faster and more reliable delivery of treatments to patients, impacting public health positively. The involvement of regulatory leaders like the FDA underscores the importance of regulatory frameworks in advancing drug development. The conference also highlights the role of technology and data in transforming healthcare, which could lead to more personalized and effective treatments.
What's Next?
Following the conference, stakeholders are expected to continue discussions on implementing the new evidence generation paradigm. The outcomes of the conference could influence future regulatory policies and industry practices. The dedicated session on C-Path's One to Millions initiative will explore scaling individualized therapies, potentially leading to broader access to innovative treatments. The conference may also result in new partnerships and collaborations across sectors, further advancing drug development efforts.
